active PsA patients continued therapy on TREMFYA® in DISCOVER 2 through 2 years (Week 100) and in DISCOVER 1 prior to Week 481*
DISCOVER 2: Study disposition at Week 24 and through Week 100
DISCOVER 1: Study disposition at Week 24 and prior to Week 48
No conclusions regarding clinical efficacy or safety can be drawn.
Reference: 1. Data on file. Janssen Biotech, Inc.
Explore TREMFYA® safety data in clinical trials